Highly efficient deletion of FUT8 in CHO cell lines using zinc‐finger nucleases yields cells that produce completely nonfucosylated antibodies
Open accessAbstract
IgG1 antibodies produced in Chinese hamster ovary (CHO) cells are heavily α1,6‐fucosylated, a modification that reduces antibody‐dependent cellular cytotoxicity (ADCC) and can inhibit therapeutic antibody function in vivo. Addition of fucose is catalyzed by Fut8, a α1,6‐fucosyltransferase. FUT8−/− CHO cell lines produce completely nonfucosylated antibodies, but the difficulty of recapitulating the knockout in protein‐production cell lines has prevented the widespread adoption of FUT8−/− cells as hosts for antibody production. We have created zinc‐finger nucleases (ZFNs) that cleave the FUT8 gene in a region encoding the catalytic core of the enzyme, allowing the functional disruption of FUT8 in any CHO cell line. These reagents produce FUT8−/− CHO cells in 3 weeks at a frequency of 5% in the absence of any selection. Alternately, populations of ZFN‐treated cells can be directly selected to give FUT8−/− cell pools in as few as 3 days. To demonstrate the utility of this method in bioprocess, FUT8 was disrupted in a CHO cell line used for stable protein production. ZFN‐derived FUT8−/− cell lines were as transfectable as wild‐type, had similar or better growth profiles, and produced equivalent amounts of antibody during transient transfection. Antibodies made in these lines completely lacked core fucosylation but had an otherwise normal glycosylation pattern. Cell lines stably expressing a model antibody were made from wild‐type and ZFN‐generated FUT8−/− cells. Clones from both lines had equivalent titer, specific productivity distributions, and integrated viable cell counts. Antibody titer in the best ZFN‐generated FUT8−/− cell lines was fourfold higher than in the best‐producing clones of FUT8−/− cells made by standard homologous recombination in a different CHO subtype. These data demonstrate the straightforward, ZFN‐mediated transfer of the Fut8− phenotype to a production CHO cell line without adverse phenotypic effects. This process will speed the production of highly active, completely nonfucosylated therapeutic antibodies. Biotechnol. Bioeng. 2010;106: 774–783. © 2010 Wiley Periodicals, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both ZFN and CRISPR/Cas9 approaches were also used for FUT8 gene-specific knockout.
“Recently, both ZFN and a CRISPR/Cas9 approaches were also used for FUT8 gene-specific knockout (Malphettes et al., 2010;Ronda et al., 2014).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Malphettes et al., 2010
Disruption of the fucosyltransferase in these cell lines completely abolished the fucosylation on the Fc domain of IgG.
“Disruption of the fucosyltransferase in these cell lines completely abolished the fucosylation on the Fc domain of IgG.”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Malphettes et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 44 · Cited by 164
Research works printed but not linked: 40
- Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. 1997. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 25(2):705-708.
- Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM. 2005. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotech- nol Prog 21(2):550-553.
- Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95(2):652-656.
- Costache M, Apoil PA, Cailleau A, Elmgren A, Larson G, Henry S, Blancher A, Iordachescu D, Oriol R, Mollicone R. 1997. Evolution of fucosyl- transferase genes in vertebrates. J Biol Chem 272(47):29721-29728.
- Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, Hocking TD, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Amacher CL. 2008. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26(6):702-708.
- Galbraith DJ, Tait AS, Racher AJ, Birch JR, James DC. 2006. Control of culture environment for improved polyethylenimine-mediated transi- ent production of recombinant monoclonal antibodies by CHO cells. Biotechnol Prog 22(3):753-762.
- Glennie MJ, Johnson PW. 2000. Clinical trials of antibody therapy. Immu- nol Today 21(8):403-410.
- Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95(12):3900-3908.
- Hamako J, Matsui T, Ozeki Y, Mizuochi T, Titani K. 1993. Comparative studies of asparagine-linked sugar chains of immunoglobulin G from eleven mammalian species. Comp Biochem Physiol B 106(4):949-954.
- Harjunpaa A, Junnikkala S, Meri S. 2000. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51(6):634-641.
- Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164(8):4178-4184.
- Ihara H, Ikeda Y, Toma S, Wang X, Suzuki T, Gu J, Miyoshi E, Tsukihara T, Honke K, Matsumoto A, et al. 2007. Crystal structure of mammalian alpha1,6-fucosyltransferase, FUT8. Glycobiology 17(5):455-466.
- Javaud C, Dupuy F, Maftah A, Michalski JC, Oriol R, Petit JM, Julien R. 2000. Ancestral exonic organization of FUT8, the gene encoding the alpha6-fucosyltransferase, reveals successive peptide domains which suggest a particular three-dimensional core structure for the alpha6- fucosyltransferase family. Mol Biol Evol 17(11):1661-72.
- Jefferis R, Lund J, Mizutani H, Nakagawa H, Kawazoe Y, Arata Y, Takahashi N. 1990. A comparative study of the N-linked oligosaccharide struc- tures of human IgG subclass proteins. Biochem J 268(3):529-537.
- Kim YG, Cha J, Chandrasegaran S. 1996. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 93(3):1156-1160.
- Leader KA, Kumpel BM, Hadley AG, Bradley BA. 1991. Functional inter- actions of aglycosylated monoclonal anti-D with Fc gamma RIþ and Fc gamma RIIIþ cells. Immunology 72(4):481-485.
- Leatherbarrow RJ, Rademacher TW, Dwek RA, Woof JM, Clark A, Burton DR, Richardson N, Feinstein A. 1985. Effector functions of a mono- clonal aglycosylated mouse IgG2a: Binding and activation of comple- ment component C1 and interaction with human monocyte Fc receptor. Mol Immunol 22(4):407-415.
- Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. 1993. Differential responses of human tumor cell lines to anti- p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37(4):255-263.
- Lim SF, Chuan KH, Liu S, Loh SO, Chung BY, Ong CC, Song Z. 2006. RNAi suppression of Bax and Bak enhances viability in fed-batch cultures of CHO cells. Metab Eng 8(6):509-522.
- Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, et al. 2007. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25(7):778-785.
- Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced anti- body-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64(6):2127-2133.
- Ohyama C, Smith PL, Angata K, Fukuda MN, Lowe JB, Fukuda M. 1998. Molecular cloning and expression of GDP-D-mannose-4,6-dehydra- tase, a key enzyme for fucose metabolism defective in Lec13 cells. J Biol Chem 273(23):14582-14587.
- Oriol R, Mollicone R, Cailleau A, Balanzino L, Breton C. 1999. Divergent evolution of fucosyltransferase genes from vertebrates, invertebrates, and bacteria. Glycobiology 9(4):323-334.
- Papac DI, Briggs JB, Chin ET, Jones AJ. 1998. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spec- trometric analysis. Glycobiology 8(5):445-454.
- Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, et al. 2008. Establishment of HIV-1 resistance Biotechnology and Bioengineering, Vol. 106, No. 5, August 1, 2010 10970290, 2010, 5, Downloaded from https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.22751 by Mount Vernon Nazarene University, Wiley Online Library on [26/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License in CD4þ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26(7):808-816. · DOI
- Raju TS, Briggs JB, Borge SM, Jones AJ. 2000. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recom- binant glycoprotein therapeutics. Glycobiology 10(5):477-486.
- Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2): 435-445.
- Ripka J, Stanley P. 1986. Lectin-resistant CHO cells: Selection of four new pea lectin-resistant phenotypes. Somat Cell Mol Genet 12(1):51-62.
- Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, et al. 2000. Unarmed, tumor- specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 97(13):7503-7508.
- Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, Holmes MC, Guschin D, Waite A, Miller JC, et al. 2008. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA 105(15):5809-5814.
- Shan D, Ledbetter JA, Press OW. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91(5): 1644-1652.
- Shan D, Ledbetter JA, Press OW. 2000. Signaling events involved in anti- CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48(12):673-683.
- Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosac- charide improves binding to human Fcgamma RIII and antibody- dependent cellular toxicity. J Biol Chem 277(30):26733-26740.
- Stanley P, Caillibot V, Siminovitch L. 1975. Selection and characterization of eight phenotypically distinct lines of lectin-resistant Chinese hamster ovary cell. Cell 6(2):121-128.
- Takahashi T, Ikeda Y, Tateishi A, Yamaguchi Y, Ishikawa M, Taniguchi N. 2000. A sequence motif involved in the donor substrate binding by alpha1,6-fucosyltransferase: The role of the conserved arginine residues. Glycobiology 10(5):503-510.
- Tateno H, Nakamura-Tsuruta S, Hirabayashi J. 2009. Comparative analysis of core-fucose-binding lectins from Lens culinaris and Pisum sativum using frontal affinity chromatography. Glycobiology 19(5): 527-536.
- Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. 2005. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435(7042):646-651.
- Walker MR, Lund J, Thompson KM, Jefferis R. 1989. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recogni- tion by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259(2):347-353.
- Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87(5):614-622.
- Ye J, Kober V, Tellers M, Naji Z, Salmon P, Markusen JF. 2009. High-level protein expression in scalable CHO transient transfection. Biotechnol Bioeng 103(3):542-551.
- Authors
- Malphettes, L., Freyvert, Y., Chang, J., Liu, P., Chan, E., Miller, J. C., Zhou, Z., Nguyen, T., Tsai, C., Snowden, A. W., Collingwood, T. N., Gregory, P. D., & Cost, G. J.
- Affiliations
- Genentech (US)
- Sangamo BioSciences (United States) (US)
- Corresponding author
- Cost, Gregory J.
- ORCID
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2010-06-21
- Volume
- 106
- Issue
- 5
- Pages
- 774-783
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2168072557
- Cited by
- 164
- References
- 44
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 7 · 2023: 8 · 2022: 11 · 2021: 10 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 13 · 2016: 10 · 2015: 8 · 2014: 13 · 2013: 10 · 2012: 16
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Biotechnology and Bioengineering (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- FUT8, alpha-1,6-fucosyltransferase, zinc finger nucleases, gene deletion, CHO cells, antibody-dependent cellular cytotoxicity, therapeutic antibodies, antibody production, stable transfection, knockout cell lines
- MeSH terms
- Animals, Antibodies, Monoclonal, Biotechnology, Cricetulus, Deoxyribonucleases, DNA, Fucosyltransferases, Genetic Techniques, Cricetinae, Zinc Fingers, CHO Cells, Gene Deletion, Cell Culture Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
